查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1451195

2024-2032 年按藥物類別、疾病類型、藥物類型、配銷通路和地區分類的憂鬱症藥物市場報告

Depression Drugs Market Report by Drug Class, Disorder Type, Drug Type, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

2023年全球憂鬱症藥物市場規模達到186億美元。展望未來， IMARC Group預計到2032年市場規模將達到246億美元，2024-2032年複合年成長率（CAGR）為3.1%。

憂鬱症是一種精神障礙，其特徵是缺乏正面情緒、持續情緒低落以及眾多認知、身體、行為和情緒症狀。透過識別症狀並檢查患者的病史來診斷。然後使用憂鬱症藥物進行治療，這種藥物可以平衡大腦中血清素等神經傳導物質的功能，並控制患者的情緒和情緒。這些藥物可以幫助緩解焦慮、季節性情感障礙和心境惡劣的症狀。

據世界衛生組織 (WHO) 稱，憂鬱症是導致殘疾的主要原因之一，影響著全球超過 2.64 億人。社交焦慮和憂鬱等精神障礙的盛行率不斷上升，是推動憂鬱症藥物市場成長的關鍵因素之一。此外，隨著各國政府實施全面封鎖並推動社交距離措施，很大一部分人口的日常生活發生了改變，進而對個人的心理健康產生了負面影響。這一趨勢已成為促進憂鬱症藥物銷售的另一個主要成長誘導因素。此外，隨著新藥物的接受度不斷提高，用於開發副作用最小和長期效果的抗憂鬱藥物的新技術的出現，預計將推動未來幾年的市場成長。

IMARC 集團的最新報告深入洞察了全球憂鬱症藥物市場，涵蓋了其所有重要方面。內容涵蓋從宏觀市場概況到微觀細節的行業表現、近期趨勢、關鍵市場促進因素和挑戰、SWOT分析、波特五力分析、價值鏈分析等。該報告是行業參與者必讀的內容，投資者、研究人員、顧問、商業策略家以及所有擁有任何利益或計劃以任何方式進入憂鬱症藥物市場的人。

本報告回答的關鍵問題

  • 全球憂鬱症藥物市場有多大？
  • COVID-19 對全球憂鬱症藥物市場有何影響？
  • 全球憂鬱症藥物市場的預期成長率是多少？
  • 推動全球憂鬱症藥物市場的關鍵因素是什麼？
  • 根據疾病類型，全球憂鬱症藥物市場的詳細情形如何？
  • 全球憂鬱症藥物市場的配銷通路分類如何？
  • 全球憂鬱症藥物市場的關鍵區域有哪些？
  • 全球憂鬱症藥物市場的主要公司/參與者有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球憂鬱症藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場區隔：依藥品類別
  • 市場區隔：按混亂類型
  • 市場區隔：依藥物類型
  • 市場區隔：按配銷通路
  • 市場區隔：按地區
  • 市場預測

第 6 章：市場區隔：依藥物類別

  • 非典型抗精神病藥
    • 市場走向
    • 市場預測
  • 血清素-正腎上腺素再攝取抑制劑 (SNRI)
    • 市場走向
    • 市場預測
  • 選擇性血清素再攝取抑制劑 (SSRI)
    • 市場走向
    • 市場預測
  • 中樞神經系統 (CNS) 興奮劑
    • 市場走向
    • 市場預測
  • 三環抗憂鬱藥
    • 市場走向
    • 市場預測
  • 單胺氧化酶抑制劑
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依無序類型

  • 嚴重憂鬱症
    • 市場走向
    • 市場預測
  • 強迫症
    • 市場走向
    • 市場預測
  • 廣泛性焦慮症
    • 市場走向
    • 市場預測
  • 恐慌症
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依藥物類型

  • 學名藥
    • 市場走向
    • 市場預測
  • 品牌藥
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥局
    • 市場走向
    • 市場預測
  • 網路藥局
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 市場走向
    • 市場預測
  • 歐洲
    • 市場走向
    • 市場預測
  • 亞太地區
    • 市場走向
    • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場預測
  • 拉丁美洲
    • 市場走向
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特的五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Otsuka Pharmaceutical
    • Pfizer
    • Eli Lilly and Company
    • AstraZeneca
    • Novartis
    • Bristol-Myers Squibb
    • GlaxoSmithKline
    • Takeda Pharmaceutical Company
    • Allergan
    • Johnson & Johnson
    • Zhejiang NHU Company Ltd
    • Sebela Pharmaceuticals
Product Code: SR112024A1563

The global depression drugs market size reached US$ 18.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.6 Billion by 2032, exhibiting a growth rate (CAGR) of 3.1% during 2024-2032.

Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.

According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years.

IMARC Group's latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global depression drugs market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on drug class, disorder type, drug type and distribution channel.

Breakup by Drug Class:

Atypical Antipsychotics

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Selective Serotonin Reuptake Inhibitors (SSRIs)

Central Nervous System (CNS) Stimulants

Tricyclic Antidepressants

Monoamine Oxidase Inhibitors

Others

Breakup by Disorder Type:

Major Depressive Disorder

Obsessive-Compulsive Disorder

Generalized Anxiety Disorder

Panic Disorder

Others

Breakup by Drug Type:

Generic Drugs

Branded Drugs

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Key Questions Answered in This Report

  • 1. What is the size of the global depression drugs market?
  • 2. What has been the impact of COVID-19 on the global depression drugs market?
  • 3. What is the expected growth rate of the global depression drugs market?
  • 4. What are the key factors driving the global depression drugs market?
  • 5. What is the breakup of the global depression drugs market based on the disorder type?
  • 6. What is the breakup of the global depression drugs market based on the distribution channel?
  • 7. What are the key regions in the global depression drugs market?
  • 8. Who are the key companies/players in the global depression drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Depression Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Class
  • 5.5 Market Breakup by Disorder Type
  • 5.6 Market Breakup by Drug Type
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Atypical Antipsychotics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Central Nervous System (CNS) Stimulants
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Tricyclic Antidepressants
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Monoamine Oxidase Inhibitors
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Disorder Type

  • 7.1 Major Depressive Disorder
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Obsessive-Compulsive Disorder
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Generalized Anxiety Disorder
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Panic Disorder
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Drug Type

  • 8.1 Generic Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Branded Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Middle East and Africa
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Latin America
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porter's Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Otsuka Pharmaceutical
    • 15.3.2 Pfizer
    • 15.3.3 Eli Lilly and Company
    • 15.3.4 AstraZeneca
    • 15.3.5 Novartis
    • 15.3.6 Bristol-Myers Squibb
    • 15.3.7 GlaxoSmithKline
    • 15.3.8 Takeda Pharmaceutical Company
    • 15.3.9 Allergan
    • 15.3.10 Johnson & Johnson
    • 15.3.11 Zhejiang NHU Company Ltd
    • 15.3.12 Sebela Pharmaceuticals

List of Figures

  • Figure 1: Global: Depression Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Depression Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Depression Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 4: Global: Depression Drugs Market: Breakup by Disorder Type (in %), 2023
  • Figure 5: Global: Depression Drugs Market: Breakup by Drug Type (in %), 2023
  • Figure 6: Global: Depression Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Depression Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Depression Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Depression Drugs Industry: SWOT Analysis
  • Figure 10: Global: Depression Drugs Industry: Value Chain Analysis
  • Figure 11: Global: Depression Drugs Industry: Porter's Five Forces Analysis
  • Figure 12: Global: Depression Drugs (Atypical Antipsychotics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Depression Drugs (Atypical Antipsychotics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Depression Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Depression Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Depression Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Depression Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Depression Drugs (Major Depressive Disorder) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Depression Drugs (Major Depressive Disorder) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Depression Drugs (Generalized Anxiety Disorder) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Depression Drugs (Generalized Anxiety Disorder) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Depression Drugs (Panic Disorder) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Depression Drugs (Panic Disorder) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Depression Drugs (Other Disorder Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Depression Drugs (Other Disorder Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Depression Drugs (Generic Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Depression Drugs (Generic Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Depression Drugs (Branded Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Depression Drugs (Branded Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Depression Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
  • Figure 41: Global: Depression Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
  • Figure 42: Global: Depression Drugs Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
  • Figure 43: Global: Depression Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
  • Figure 44: Global: Depression Drugs Market: Sales through Online Pharmacies (in Million US$), 2018 & 2023
  • Figure 45: Global: Depression Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2024-2032
  • Figure 46: Global: Depression Drugs Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
  • Figure 47: Global: Depression Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
  • Figure 48: North America: Depression Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: North America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Depression Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Depression Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Asia Pacific: Depression Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Asia Pacific: Depression Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Middle East and Africa: Depression Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Middle East and Africa: Depression Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Latin America: Depression Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Latin America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Global: Depression Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Depression Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Depression Drugs Market Forecast: Breakup by Disorder Type (in Million US$), 2024-2032
  • Table 4: Global: Depression Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 5: Global: Depression Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Depression Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Depression Drugs Market Structure
  • Table 8: Global: Depression Drugs Market: Key Players